Notizie Ypsomed Italia

Varese - Ypsomed Italia, sensibile alle problematiche sociali e responsabilmente attiva, in questo delicato momento, nella lotta alla diffusione dell’epidemia da COVID-19, ha deciso di ridurre o sospendere le attività normalmente svolte a contatto con il pubblico e con gli operatori sanitari, presso le strutture sanitarie ambulatoriali e/o di degenza. Per lo stesso motivo precauzionale abbiamo sospeso tutti i meeting e le partecipazioni a convegni e congressi, fino a data da destinarsi.

Teva has announced the launch of AJOVY in an autoinjector device for the German market in March 2020.
AJOVY autoinjector

Press Releases Ypsomed Group

Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including central nervous system, pain and respiratory, launches its drug product AJOVY® in the pre-filled YpsoMate 2.25 autoinjector from Ypsomed. AJOVY® is used for the preventive treatment of migraine in adults. The collaboration with Teva marks the first commercial market entry of Ypsomed’s larger 2.25 ml autoinjector YpsoMate 2.25.

Disponibilità fornitura gratuita aghi penna insulina

Coronavirus e diabete

Notizie Ypsomed Italia

Varese - Anche Ypsomed Italia, filiale italiana della multinazionale svizzera impegnata nello sviluppo e nella produzione di sistemi di auto-somministrazione di insulina, si unisce al coro di aziende scese in campo per sostenere il sistema sanitario italiano, e soprattutto lombardo, messo a dura prova in queste settimane dalla crisi coronavirus.

Press Releases Ypsomed Group

We are monitoring the global development after the outbreak of the Coronavirus very closely. Our highest priority is our business continuity and the reliable supply of our products as well as the safety of our employees. We can confirm that to date there is no impact on the supply of our products and that our production sites are fully operational.

Press Releases Ypsomed Group

Burgdorf – Ypsomed is recording weaker growth in the insulin pump business and is adjusting its approval strategy with the American FDA. In addition, Ypsomed is reducing its EBIT outlook for the current financial year 2019/20 to CHF 9 million due to one-time and temporary effects. Ypsomed confirms its mid-term EBIT target of CHF 100 million.